Day One Biopharmaceuticals, Merck sign licensing deal for MEK Inhibitors
Day One Biopharmaceuticals has signed a licensing agreement with Merck to develop and commercialize pimasertib and MSC2015103B, two oral, small molecule allosteric inhibitors of MEK ... Read More